Loading clinical trials...
Loading clinical trials...
Effects of Intranasal Oxytocin on Trust Towards Therapists and Dogs: A Randomized Controlled Trial in Healthy Adults
Oxytocin has been proposed as a neuroendocrine mechanism that may mediate the relationship between dog ownership and positive health outcomes and be linked to human-dog interactions and is thought to be a mechanism of interspecies bonding. While the role of oxytocin in human bonding behaviours and social behaviour, in general, is becoming well-established the role of oxytocin in human-animal interaction and Animal-Assisted Interventions (AAI) remains unclear. This research gap calls for more high-quality research investigating this possible neuroendocrine underlying mechanism to advance knowledge about AAI. If oxytocin indeed might be involved in interspecies bonding, intranasally administered oxytocin should not only enhance trust toward a human but also towards a dog.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
University of Basel
Basel, Canton of Basel-City, Switzerland
Start Date
January 29, 2024
Primary Completion Date
December 31, 2024
Completion Date
December 31, 2024
Last Updated
November 5, 2024
176
ESTIMATED participants
Oxytocin nasal spray
DRUG
Animal-Assisted Intervention
OTHER
Placebo
DRUG
Lead Sponsor
Dr. Karin Hediger
NCT04123314
NCT06574035
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions